Purpose. In the present study, enhancement of the the antibacterial activity of ceftriaxone against Gram-positive (meticillinresistant Staphylococcus aureus; MRSA) and Gram-negative (Escherichia coli) bacteria with a biodegradable polymer was attempted.
INTRODUCTION
With the evolution of mankind, diseases also emerged. Some common diseases have become rare, while some rare diseases have become common, and new types have also evolved. Human civilization has played the key role in many of these important transformations [1] .
There are a few common microbes like Staphylococcus aureus, a Gram-positive positive aerobe that are normally responsible for some bloodstream infections, as well as, for example, pneumonia, soft-tissue infections and skin infections [2] . Similarly another organism, Escherichia coli, a Gram-negative aerobe, is a frequent cause of bacterial infection in both animals and human. In humans, it is a common commensal resident bacteria of the gastrointestinal tract, and is also linked with community-associated and nosocomial infections [3] . Its common clinically significant infections include urinary-tract infection, neonatal meningitis, sepsis and invasive extra-intestinal infections.
Inappropriate usage and increased utilization of antimicrobial agents have accelerated the antimicrobial resistance in microbes [4] . Overuse, misuse and the use of empiric antibiotic therapy have led to an increase in the resistance of bacteria to many different antibiotics, thus increasing the rate of life-threating illnesses [5] .
Because of this misuse, meticillin-resistant S. aureus (MRSA) is becoming more common and is implicated in causing severe infections including osteomyelitis, bloodsteam infections, soft tissue infections, endovascular infections and meningitis. MRSA strains are resistant to most of the classes of b-lactam antibiotics and different antimicrobial agents like aminoglycosides, clindamycin, macrolides, chloramphenicol and fluoroquinolones [6] . Emergence of vancomycin-resistant S. aureus has further limited the treatment options against MRSA infections [7] . Surprisingly, the rate of antibiotic resistance in E. coli is also rising quite rapidly, especially with respect to third-generation cephalosporins, fourth-generation cephalosporins and fluoroquinolones [8] . Resistance against b-lactam antibiotics (after their introduction as an antimicrobial agent) has also emerged in different strains of E. coli by the production of b-lactamases.
In Pakistan, doctors mostly prescribe ceftriaxone for the treatment of urinary-tract infections and respiratory-tract infections. This frequent use of antibiotics has led to an increased emergence of resistance in E. coli and MRSA. So there is a need for alternative drug regimens to overcome the resistance problem [9] .
Chitosan, which is a natural cationic polysaccharide, is biodegradable, produces nontoxic degradable products and provides sustained release of drugs at a specific target site, is commonly used for the modification of drug formulations. Moreover, this polymer has its own antimicrobial activity against both Gram-positive bacteria (S. aureus, Streptococcus pyogenes, MRSA) and Gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa) [10, 11] . Its cross-linking ability helps in the development of nanoparticles of chitosan, which have better antibacterial activity then chitosan alone [12] . Its drug-loading ability makes it a good carrier for different drugs and drug-loaded chitosan nanoparticles (CNPs) have shown enhanced antibacterial activity against S. aureus and E. coli in some previous studies [12, 13] . The current study evaluated the antimicrobial effect of ceftriaxone alone and blank CNPs and the expected synergistic effect of ceftriaxone-loaded CNPs against resistant strains of MRSA and E. coli obtained from hospitalized patients.
METHODS
Deacetylated chitosan (Sigma Aldrich) of low molecular mass, soluble in diluted aqueous acid solution, was used for making nanoparticles along with a linker, pentasodium tripolyphosphate (TPP) (Sigma Aldrich). Ceftriaxone and acetic acid were obtained from Cirin Pharmaceuticals.
Sample collection and identification
MRSA and E. coli samples were collected from the Holy Family Hospital, Rawalpindi, Pakistan, and different standard microbiological techniques were used for their processing. Identification of these strains was made on the basis of growth in different growth media, including mannitol salt agar (Sigma) for MRSA and MacConkey agar (Sigma) for E. coli. Different biochemical tests were performed for Gram-positive and -negative bacteria, including catalase, coagulase, triple sugar iron, citrate and indole tests. Strains that were isolated on selective growth media and those that showed positive biochemical tests were further confirmed by molecular techniques by targeting specific genes in MRSA and E. coli. The controls used were MRSA 252 and E. coli ATCC 15224.
The isolated bacterial colonies of MRSA were subjected to molecular identification using mecA and nucA primers selected from previous studies [14, 15] . E. coli were also subjected to molecular identification by PCR using uspA primers selected from a previous study [16] , for the gene encoding universal stress protein A. DNA was extracted with a Wizard genomic DNA purification kit (Promega) according to the manufacturer's manual. The isolated DNA was stored at 2 to 8 C.
The same PCR thermal cycling conditions were used for mecA and nucA primers. Preheating was carried out at 95 C for 4 min; followed by 30 cycles of denaturation at 95 C for 30 s, annealing at 52 C for 1 min and extension at 72 C for 2 min. The final extension of the PCR was carried out at 72 C for 7 min.
PCR amplifications with the uspA primer were performed under the following thermal cycling conditions: initial DNA denaturation at 94 C for 5 min; followed by 30 cycles of denaturation at 94 C for 1 min, annealing at 55 C for 1 min and extension at 72 C for 2 min; followed by final extension at 72 C for 5 min. All primers were obtained from e-Oligo (Gene Link).
Agarose gel (1 %) was used to analyse the PCR products. The amplified PCR fragments were compared with a 1 kb DNA ladder (Fermentas). The gel was run at 100 V for 30 min and observed with the molecular imaging gel Doc XR+ system (Uvitec).
Antimicrobial-susceptibility testing Antibiotic-susceptibility testing was performed according to the guidelines of the European Committee on Antimicrobial Susceptibility Testing [17] . For disc diffusion susceptibility testing, inocula were prepared on Mueller-Hinton agar (MHA) (Sigma Aldrich) for the determination of the antimicrobial susceptibility of all the isolates of MRSA and E. coli. Cefoxitin, ceftriaxone, cefradine, ciprofloxacin, erythromycin, imipenem, levofloxacin, linezolid, oxacillin, quinupristin/dalfopristin, tetracycline and vancomycin antibiotic discs (from Oxoid) were used to identify the susceptible or resistant bacterial cultures depending upon their zones of inhibition (ZOIs). Etest was also used to determine antimicrobial susceptibility to ceftriaxone.
Ceftriaxone was selected for the present study on the basis of its susceptibility pattern against both Gram-positive and -negative strains and its water solubility, a suitable property for its incorporation in CNPs for further enhancement of antibacterial activity. The MIC for ceftriaxone was determined by agar dilution, agar well diffusion and E-strip methods. Different stock solutions of varying antibiotic strength were prepared by the serial dilution method. Petri plates of different concentrations ranging from 0.125 to 1024 mg l À1 were prepared for both agar dilution and agar well diffusion. A breakpoint concentration of 2 mg l À1 was used for both the strains. E-strips of ceftriaxone (Oxoid) were used, having a MIC range from 0.002 to 32 µg ml
À1
.
Preparation of CNPs and ceftriaxone-loaded CNPs
CNPs were prepared by the ionic gelation method, with 0.3 % chitosan in 2 % acetic acid solution and 0.1 % TPP solution. CNPs were obtained by drop wise addition of 4 ml TPP solution into 10 ml chitosan solution, with continuous magnetic stirring at 800 r.p.m. The pH of the solution was raised to 5 and the solution was continuously stirred at room temperature for 30 min to obtain CNPs. The CNPs formed were collected by centrifugation at 10 000 g for 20 min. The CNPs were dispersed in 1 % cryoprotectant and were again centrifuged at 10 000 g for 20 min. Finally, the CNPs were lyophilized and dispersed in sterile distilled water. For preparation of ceftriaxone-loaded CNPs, ceftriaxone at two times its breakpoint MIC was dissolved in 4 ml TPP solution and added dropwise into the chitosan solution.
Characterization of CNPs and ceftriaxone-loaded CNPs Scanning electron microscopy (SEM) of CNPs and ceftriaxone-loaded CNPs was performed using a Jeol JSM 6490A scanning electron microscope at Â200-1000 magnification and 20 kV resolution. Transmission electron microscopy (TEM) was performed with a Jeol JEM-1010, for morphological evaluation of both CNPs and ceftriaxone-loaded CNPs. Fourier transform infrared spectroscopy (FTIR) spectra for CNPs and ceftriaxone-loaded CNPs were recorded in the range 4000 to 600 cm À1 at a resolution of 4 cm À1 by using a FTIR analyser (Perkin Elmer). X-ray powder diffraction (XRD) patterns of both CNPs were obtained from a diffractometer (model X¢ Pert Pro; PANalytical). The X-ray source was CuKa radiation and diffractograms of a thin layer of freeze-dried sample were obtained over the range of 10 <2<70 at a scanning rate of 0.4 min
À1
. A Malvern Zetasizer (NanoZS) was used to determine the zeta potential and polydispersity index of both types of nanoparticle.
Determination of loading efficiency (LE) and entrapment efficiency (EE)
The LE and EE of CNPs and ceftriaxone-loaded CNPs were determined with the help of a UV spectrophotometer at 258 and 266 nm using the following formulas.
EE ð%Þ ¼
Total ceftriaxone Na À Free ceftriaxone Na Total ceftriaxone Na Â100
LC ð%Þ ¼ Total ceftriaxone Na À Free ceftriaxone Na Weight of nanoparticles Â100
Antimicrobial-susceptibility and time-kill assays with CNPs and ceftriaxone-loaded CNPs The enhanced antimicrobial effects of CNPs and ceftriaxone-loaded CNPs against ceftriaxone-resistant MRSA and E. coli were determined through agar well diffusion and time-kill assay. In agar well diffusion, overnight grown MRSA and E. coli cultures were taken and resuspended in sterile distilled water at a concentration of 10 7 c.f.u. and compared with a 0.5 McFarland standard solution. Then, 20 ml MHA was poured into each Petri plate. A bacterial lawn was made on the agar. With the help of a sterile corkborer, 18 mm wells were made in the agar and 50 µl of each CNPs and ceftriaxone-loaded CNPs suspension, along with the control and the solvent used, was transferred into the wells. The suspension was allowed to absorb into the MHA medium, and after that the plates were inverted and kept in an incubator at 37
C for 16-18 h. The diameter of the ZOI was noted for every sample.
The time-kill assay assessed the viability of test organisms with CNPs and ceftriaxone-loaded CNPs over a specific time period. The assay was performed with macro-dilution according to the method recommended by the Clinical and Laboratory Standards Institute with a few modifications. Overnight grown bacterial cells were taken and diluted to 10 7 c.f.u. ml À1 via comparison with a 0.5 McFarland standard solution and optical density measurements in a UV spectrophotometer. The CNPs and ceftriaxone-loaded CNPs suspension in 500 µl volume was added to the inoculum suspension accordingly. Mueller-Hinton broth inoculated with each bacterial strain without ceftriaxone and the nanoparticles were used as controls. The bacterial cultures were incubated at 37 C in a shaker incubator at 200 r.p.m. and 200 µl samples were taken from each culture at the time points 0, 1, 2, 3, 4, 8 and 24 h. Then, the bacterial samples were 100-fold serially diluted in normal saline and 50 µl sub-cultured from each dilution onto MHA plates. Colonies were counted and viable counts were calculated as c.f.u. ml À1 . The time-kill curve was plotted with time against the log 10 c.f.u. ml À1 concentration. The experiment was performed and analysed in triplicate.
In vivo assay in a neutropenic mouse thigh model Neutropenia was caused in mice by injecting cyclophosphamide into the intra-peritoneal cavity at time 0 and on the third day with a dose of 150 mg (kg body weight)
À1
. On the fourth day, infection was caused in each thigh of mice by injecting 0.1 ml inoculum (MRSA and E. coli). For inoculum preparation, the bacterial isolates were cultured overnight on MHA, then 2-3 colonies were suspended in normal saline solution to give the concentration 10 7 to 10 8 c.f.u. ml
. For each bacterial strain, the female Swiss albino mice (mean weight 30 g) were divided into five subgroups containing five mice in each group (both for MRSA and E. coli). The first group (negative control) did not receive any treatment nor infection. The second group (positive control) was infected with the bacterial isolates (MRSA and E. coli) and treated with only normal saline solution. The third, fourth and fifth groups were infected with test organisms (MRSA and E. coli) and were treated with ceftriaxone, CNPs and ceftriaxone-loaded CNPs, respectively.
After 2 h infection, the normal saline solution, ceftriaxone solution, CNPs and ceftriaxone-loaded CNPs were injected intramuscularly in each thigh at various time intervals. On the fourth day of infection, the mice were sacrificed by cervical dislocation and the thighs were dissected, separated and homogenized in 10 ml iced-chilled sterile normal saline. For determination of the number of c.f.u., 1000-fold serial dilutions of the homogenized thigh tissues were plated on MHA and incubated overnight at 37 C. 
MTT (methylthiazolyldiphenyl tetrazolium

Statistical analysis
Data obtained are presented as the mean ±SD. The data were also analysed with independent t-tests and Waller-Duncan tests by using SPSS 17. P values of <0.05 indicated statistical significance between the tested groups.
RESULTS
Sample collection and identification A total of 24 clinical samples of MRSA and 30 clinical samples of E. coli were initially collected from the Microbiology Department, Holy Family Hospital, Rawalpindi, Pakistan, and were grown on MHA for further identification. Out of all these samples, 12 resistant strains each of MRSA and E. coli were selected for further studies.
Based on biochemical identification tests, strains of MRSA and E. coli were confirmed and were subjected to further processes. MRSA colonies gave a yellow zone on mannitol salt agar, and b-haemolysis on sheep blood agar, with positive catalase and coagulase tests; while E. coli appeared as light-pink colonies with well-defined shape on MacConkey agar, with positive triple sugar iron and indole tests and a negative citrate test.
For molecular identification, DNA was extracted from all the 12 strains of MRSA and E. coli. MRSA was identified by amplifying mecA and nucA genes, giving amplicons at 533 and 270 bp, respectively, while the uspA gene in E. coli was successfully identified, with an 884 bp amplicon.
Antimicrobial-susceptibility testing All isolates of MRSA appeared strongly resistant (100 %) to cefoxitin and oxacillin, while the resistance pattern to ceftriaxone, erythromycin and tetracycline was 75 to 92 %. For ciprofloxacin and levofloxacin, the isolates showed intermediate resistance (50 %). All isolates of E. coli showed 100 % resistance to erythromycin, linezolid, oxacillin and vancomycin. For ceftriaxone, cefradine, ciprofloxacin and cefoxitin, the E. coli isolates showed 66 to 83 % resistance. Total (100 %) susceptibility was seen only with imipenem.
MICs with ceftriaxone
Among the 12 isolated strains of MRSA, only 2 (16.7 %) strains showed susceptibility to ceftriaxone, while the remaining 10 (83.3 %) strains were resistant, and the MIC ranged from 0.5 to 1024 mg l À1 with a statistically significant t-test result (t=À2.569, P=0.026). The E. coli isolates also showed the same MIC pattern as MRSA, that is 2 (16.7 %) were susceptible and 10 (83.3 %) were resistant. The t-test on the MIC results of E. coli was also statistically significant (t=À2.253, P=0.046) ( Table 1 ). In the case of agar well diffusion, ceftriaxone showed no ZOI at a dilution of 0.1 mg ml
À1
, while at 0.5 and 1 mg ml À1 significant ZOIs were shown, which were indicative that at those higher concentrations the bacteria were susceptible. E-strip tests showed no ZOI around the strip, confirming the resistance of both MRSA and E. coli to ceftriaxone. Further studies were conducted against the ceftriaxone-resistant strains (10 each of MRSA and E. coli). Characterization of CNPs and ceftriaxone-loaded CNPs SEM photographs showed hemispherical nanoparticles both in blank CNPs (magnification Â50 000) (Fig. 1a) and ceftriaxone-loaded CNPs (magnification Â10 000) (Fig. 1b) .
TEM photographs showed irregular and spherical nanoparticles both in blank CNPs at Â10 000 resolution (Fig. 1c) and ceftriaxone-loaded CNPs at Â25 000 resolution (Fig. 1d) .
In FTIR, vibrational analysis was performed to confirm the attachment of drug within the CNPs. The infrared spectra for blank CNPs and ceftriaxone-loaded CNPs were recorded at ambient temperatures and are shown in Fig. 2(a) .
In Fig. 2(a) , the upper IR pattern is that of the blank CNPs, while the lower one is that of the ceftriaxone-loaded CNPs. All the characteristic absorption peaks of chitosan were observed as 3416 cm À1 (O-H and N-H), 2925 cm [19, 20] .
The XRD analysis was performed to ensure the presence of chitosan and ceftriaxone in the sample. The diffraction patterns of both blank CNPs and ceftriaxone-loaded CNPs are shown in Fig. 2(b) . In both patterns, the intensity of noise was very high, which indicates that both materials (chitosan and ceftriaxone) are polycrystalline in nature [21] . Thus, the peaks of ceftriaxone might have been hidden or overlapped with those of chitosan. The pattern D (ceftriaxone-loaded CNPs) also shows that chitosan existed in its original form and neither reacted with ceftriaxone nor decomposed in the loaded sample. The zeta potentials of blank and ceftriaxoneloaded CNPs showed moderate to good stability. The blank CNPs (size 68 nm) had a value of À46.22 mV (Fig. 3a) , while ceftriaxone-loaded CNPs (size 220 nm) had a value of À36.88 mV (Fig. 3b) .
Determination of LE and EE
The mean LE (%) of the blank CNPs was about 30-35 % and of ceftriaxone-loaded CNPs was about 40-45 %, and the mean EE (%) of CNPs was 25-30 % and of ceftriaxone-loaded CNPs was about 35-40 % (Table 2) .
Antibacterial-susceptibility and time-kill assays with CNPs and ceftriaxone-loaded CNPs All the strains of MRSA were resistant to the 0.1 mg ml À1 dilution of ceftriaxone with no ZOI, while the blank CNPs and ceftriaxone-loaded CNPs against MRSA showed mean diameters of 17.1 and 23.8 mm, respectively, as shown in Fig. 4(a) . Similarly, the 0.1 mg ml À1 dilution of ceftriaxone against E. coli did not show any ZOI, while the mean diameters of the ZOIs against E. coli blank CNPs and ceftriaxone-loaded CNPs were 14.8 and 25.1 mm, as shown in Fig. 4(b) . Acetic acid was used as a positive control and sterilized distilled water as a negative control in this experiment.
In the time-kill assay, the concentration of ceftriaxone used alone as well as incorporated in the CNPs was two times its breakpoint MIC. The viability of MRSA reduced by~1 log 10 over 24 h with treatment with ceftriaxoneloaded CNPs, while the same formulation reduced the viability of E. coli by~2.5 log 10 over 24 h, as can be seen in Fig. 4(c, d) . In contrast, treatment with blank CNPs showed a gradual increase in viability by~1 log 10 in the case of both isolates. Ceftriaxone alone reduced the viability of MRSA and~1.5 log 10 reduction was noticed during the first hour, then a~2 log 10 increase was seen until 24 h treatment (as shown Fig. 4c) , while in the case of E. coli the growth was inhibited until 8 h then an~2 log 10 increase was seen (as shown in Fig. 4d ).
In vivo assay in a neutropenic mouse thigh model In the negative control group, the bacterial load was zero as no pathogen was administered, while the positive control group showed the highest rate of~8 log 10 c.f.u. ml À1 for MRSA and~8.5 log 10 c.f.u. ml À1 for E. coli, which was considered as 100 % growth. Among the groups treated with blank CNPs, ceftriaxone-loaded CNPs and ceftriaxone, only the group treated with ceftriaxone-loaded CNPs showed a significant decrease (P<0.05) in microbial burden, almost 41 % for MRSA infection and 27 % in the case of E. coli infection. The other groups showed a very slight change in microbial burden as compared to the positive control (Fig. 5 ).
MTT assay with the MCF-7 cell line No significant difference in toxicity of CNPs and ceftriaxone-loaded CNPs was seen with the MCF-7 cell line. As compared to the negative control, the blank CNPs showed a slight decrease in the viability of MCF-7 cells ranging from 87 to 83 % as the concentration was increased gradually from 4 to 20 µg ml À1 . Ceftriaxone-loaded CNPs also showed a slight reduction in the percentage viability, which ranged from 88 to 81 % with the increase of concentration from 4 to 20 µg ml À1 , as clearly seen in Fig. 6 . 
DISCUSSION
MRSA and E. coli are common causes of infection and their increasing resistance to different antibiotics has limited the number of available antibiotics that can treat infections caused by these organisms. The purpose of this study was to formulate and evaluate ceftriaxone-loaded CNPs in an attempt to reduce the antibacterial resistance of MRSA and E. coli against ceftriaxone.
PCR analysis successfully identified MRSA with nucA-and mecA-positive isolates, similar to the study by Al-Zahrani and colleagues [22] . E. coli was identified by amplifying uspA, similar to a previous study by Osek and colleagues [23] . In the current study, the MRSA strains were highly resistant to most of the antibiotics except linezolid, quinupristin/dalfopristin and vancomycin. Similar susceptibility with linezolid and vancomycin was seen in some previous research [24, 25] . In the present study, MRSA strains were less resistant to antibiotics as compared to an older report [24] . However, the E. coli strains were more resistant to antibiotics than MRSA except for imipenem, for which E. coli strains showed susceptibility. A previous study showed a similar high resistance to antibiotics in E. coli [26] . In this, the bacteria showed moderate susceptibility to imipenem, while in the present study high susceptibility was shown.
The present study showed a very high MIC for ceftriaxone (MIC !1024 mg l
À1
) against both MRSA and E. coli. A recently conducted study reported a 32 µg ceftriaxone ml À1 MIC for MRSA isolates, which is comparatively less than in the present study [27] . Similar findings were highlighted as well by some other studies on S. aureus [28] . For E. coli, the same high MIC with ceftriaxone (0.16 to >256 mg l À1 ) was reported in a similar study [29] . Different ratios of chitosan : TPP were used to prepare nanoparticles and the best ratio for blank CNPs found was 3 : 1; the same ratio was used for making ceftriaxone-loaded CNPs with 1 mg ceftriaxone ml
. The drug concentration was selected on the basis of the ceftriaxone MIC shown with the strain. A similar ratio of chitosan : TPP was used in a previous study for making CNPs [30] .
Both blank CNPs and ceftriaxone-loaded CNPs showed a typical size, which was 1 to 1000 nm, and a polydispersity index of less than 0.5, indicating that the formulation contained a homogenous nanoparticle size distribution profile. The zeta potential ±30 mV indicated the blank and ceftriaxone-loaded CNPs were physically stable. All these results were similar to those of a previous study [31] . TEM and SEM results revealed that the particles appeared irregular and spherical shaped for the reason that before observation, they were not purified and excess of polymer might interfere in the characterization process. This present finding was similar to the findings of a previous study [32] .
The results of XRD were helpful in revealing loading of ceftriaxone in CNPs. The original peaks of chitosan were unchanged, which illustrated that the chitosan binding did not harm ceftriaxone, that is, no phase change of ceftriaxone was observed. A previous study showed a similar pattern of XRD with CNPs differential peaks [33] .
The FTIR technique determined the relationship between CNPs and ceftriaxone, and showed the presence of ceftriaxone in CNPs. The additional characteristic peaks, like C-H, N=C and C=C stretching and -CH bending, indicated the presence of ceftriaxone in CNPs. Similarly, additional peaks were seen in some older studies [34] .
The antimicrobial susceptibility assay of ceftriaxone-loaded CNPs showed much higher antibacterial activity than for CNPs and ceftriaxone alone, indicating that the antibacterial activity was significantly enhanced by the loading of ceftriaxone in CNPs, which may be due to the combined antibacterial effect of both chitosan and ceftriaxone. ZOIs with ceftriaxone alone against resistant strains were initially zero but with the drug loaded in CNPs, drug at the same concentration showed significant ZOIs, which indicated that the activity of the drug was enhanced after loading in CNPs. The mean diameters of the ZOIs for MRSA with blank and ceftriaxone-loaded CNPs were 17±2 and 23.8±2 mm, while for E. coli they were 14.8±2 and 25.1±2 mm, respectively, which were higher than the ZOIs with ceftriaxone. The results in the present study were similar to those of a previous report on ceftriaxone-loaded CNPs that showed enhanced antibacterial activity of ceftriaxone-loaded CNPs against Salmonella typhimurium [35] , but in the present study this activity was evaluated against both Gram-positive and Gram-negative organisms.
The time-kill assay showed a reduction in bacterial viability with ceftriaxone-loaded CNPs against MRSA and E. coli. More effective killing was seen against MRSA than E. coli; this may be due to differences in cell-wall structure. Blank CNPs did not reduce the viability of both the bacteria, but inhibited the growth over time. A similar study reported higher killing rates for both MRSA and E. coli with CNPs than the present study [36] . In this former study, bacterial growth inhibition was more rapid in the initial hours, with a progressive decrease afterwards that was~8 log 10 reductions in 8 h. This difference may be associated with the particle size of the nanoparticles, which in the former study was much higher than in the present study. Similar effects were seen during the in vivo study, where a reduction in microbial burden was seen in mice thighs that had been treated with ceftriaxone-loaded CNPs. These findings may be helpful in developing new antimicrobial regimens for clinical use.
CNPs and ceftriaxone-loaded CNPs showed low toxicity against breast cancer cells in the present study. CNPs were reported to have low toxicity against MCF-7 breast cancer cells in some previous studies [37, 38] . In addition, it has been reported that CNPs and loaded CNPs showed higher toxicity than chitosan against tumour cells than on normal cells, but this depended upon the size and concentration [39] .
Conclusion
The results based on in vitro and in vivo studies revealed that blank CNPs possessed their own slight antibacterial activity against resistant strains of both Gram-positive and Gram-negative bacteria, and when ceftriaxone was loaded in the CNPs the response of the drug was enhanced. This synergistic effect at a reduced dose of ceftriaxone with chitosan is a useful finding for antibiotic-dose reduction and cost-effective treatment against resistant microbes.
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